EGFR and ovarian carcinoma: The knowledge derived from retospective studies like this one should be used in the design of prospective trials investigating the value of EGFR/HER2-neu directed molecular treatments in epithelial ovarian cancer including the need for more uniform definitions of gene amplification and polysomy and selection of a patient population with a known altered gene status.